Biogen Canada Inc. announced today that Health Canada has issued marketing authorization with conditions (Notice of Compliance with Conditions (NOC/c)) for QALSODY™ (tofersen injection) for the ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

The murder of UnitedHealthcare CEO Brian Thompson in December sparked growing public anger over insurers denying coverage and ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

The drug – branded as Qalsody – is the first therapy to be approved for a genetic form of ALS, and is also notable for being the first neurology therapeutic for which a blood biomarker has ...

Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Health regulators in Canada gave conditionally approval to Qalsody to treat adults whose ALS is due to mutations in the SOD1 ...

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. Following our analysis of the options activities associated with ...

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...